Brief: Zenocutuzumab Granted Breakthrough Therapy Designation By The U.S. Food & Drug Administration For The Treatment Of NRG1+ Pancreatic Cancer

Merus NV

29/06/2023 23:13

June 29 (Reuters) - Merus NV  MRUS.O :
    * ZENOCUTUZUMAB (ZENO) GRANTED BREAKTHROUGH THERAPY
DESIGNATION BY
THE U.S. FOOD & DRUG ADMINISTRATION FOR THE TREATMENT OF NRG1+
PANCREATIC CANCER
    * MERUS NV- MERUS PLANS TO PROVIDE INITIAL CLINICAL DATA ON
ZENO
IN CRPC IN SECOND HALF OF 2023

Source text for Eikon:  ID:nGNX8N0SsB 
Further company coverage:  MRUS.O 

 ((Reuters.Brief@thomsonreuters.com;))